Note 8 - Shareholders' Equity (Tables)

3 Months Ended

Jun. 30, 2024

Statement of Stockholders' Equity [Abstract]

Schedule of Derivative Liabilities at Fair Value

The derivative warrant liabilities are measured at fair value at each reporting period and the reconciliation of changes in fair value is presented in the following table:

	June 30, 2024	June 30, 2023
	$	$
Beginning balance	4,359	—
Change in fair value	(1,395)	—
Ending balance	2,964	—

Fair Value Measurement Inputs and Valuation Techniques

The warrant liability was determined based on the fair value of warrants at the issue date and the reporting dates using the Black-Scholes model with the following weighted-average assumptions that will expire on the earlier of (i) the 60th day after the date of the acceptance by the U.S. Food and Drug Administration of a New Drug Application for the Company's product candidate GTX-104 or (ii) five years from the date on issuance.

	June 30, 2024	March 31, 2024
Risk-free interest rate	4.94%	4.69%
Share price	$2.92	$3.43
Expected warrant life	1.78	2.03
Dividend yield	0%	0%
Expected volatility	79.11%	85.94%